Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Public ClinicalTrials.gov record NCT01736683. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of improvement of anemia in patients diagnosed with low- or intermediate-1 risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML).
Study identification
- NCT ID
- NCT01736683
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 28, 2012 (Actual)
- Primary completion
- Apr 30, 2018 (Actual)
- Completion
- Apr 30, 2018 (Actual)
- Last update posted
- Oct 24, 2022
2012 – 2018
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Center-Midtown | Denver | Colorado | 80218 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Johns Hopkins | Baltimore | Maryland | 21231 | — |
| Dana-Farber / Harvard Cancer Institute | Boston | Massachusetts | 02215 | — |
| Monter Cancer Center, North Shore LIJ Health Systems | Lake Success | New York | 11042 | — |
| Columbia University Medical Center/New York-Presbyterian Hospital | New York | New York | 10032 | — |
| The Cleveland Clinic Foundation Hematology and Medical Oncology Rm 35 | Cleveland | Ohio | 44195 | — |
| Sarah Cannon Research Inst | Nashville | Tennessee | 37203 | — |
| Texas Oncology Round Rock Cancer Center - Round Rock | Round Rock | Texas | 78681 | — |
| University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | — |
| Texas Oncology, P.A. - Tyler | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Yakima Valley Memorial Hospital/ North Star Lodge | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01736683, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2022 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01736683 live on ClinicalTrials.gov.